An object of the present invention is to discover a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer contains as an active ingredient, the following (i) or (ii): (i) at least one polypeptide having an immune-inducing activity and selected from the group of polypeptides (a) or (b), where: (a) polypeptides consisting of 7 or more consecutive amino acids within the region of positions 24 to 97 in the amino acid sequence represented by SEQ ID NO: 2; and (b) polypeptides comprising one to several amino acid deletions, substitutions and/or additions in the amino acid sequence of any one of the polypeptides (a); and (ii) a recombinant vector comprising at least one polynucleotide encoding any one of the polypeptides, and capable of expressing the polypeptide in vivo.

An object of the present invention is to discover a novel peptide useful as an active ingredient in an agent for treating or preventing cancer, and to provide the use of the polypeptide as an immune inducer. The immune inducer contains as an active ingredient, the following (i) or (ii): (i) at least one polypeptide having an immune-inducing activity and selected from the group of polypeptides (a) or (b), where: (a) polypeptides consisting of 7 or more consecutive amino acids within the region of positions 24 to 97 in the amino acid sequence represented by SEQ ID NO: 2; and (b) polypeptides comprising one to several amino acid deletions, substitutions and/or additions in the amino acid sequence of any one of the polypeptides (a); and (ii) a recombinant vector comprising at least one polynucleotide encoding any one of the polypeptides, and capable of expressing the polypeptide in vivo.

The present invention has a purpose of providing a novel β-galactosidase enzyme useful for the production of oligosaccharides. Disclosed is a β-galactosidase enzyme comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 or an amino acid sequence that is 80% or more identical to said amino acid sequence.

The present invention has a purpose of providing a novel β-galactosidase enzyme useful for the production of oligosaccharides. Disclosed is a β-galactosidase enzyme comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 4 or an amino acid sequence that is 80% or more identical to said amino acid sequence.

Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.

Disclosed is a method for production of a fusion protein in which an antibody and a lysosomal enzyme are fused. The method comprises; (a) a step of culturing mammalian cells producing the fusion protein in a serum-free medium to let the mammalian cells secrete the fusion protein in the culture medium, (b) a step of collecting culture supernatant by removing the mammalian cells from the culture medium, and (c) a step of purifying the fusion protein from the culture supernatant by using a column chromatography employing as a solid phase a material to which a substance having affinity for the fusion protein has been bound, a column chromatography employing as a solid phase a material having affinity for the phosphate group, and a size exclusion column chromatography.

In an embodiment, the invention provides a method and reagents for detection of γ-herpesvirus circRNA. In another embodiment, the invention provides a method and reagents for detection of EBV circRNA. In still another embodiment, the invention provides a method and reagents for detection of KSHV circRNA. The method can be expanded to other herpesviruses and even non-herpesviruses that generate circRNA upon cellular infection.

A method of biochip production includes a step A of applying a solution containing a selective binding substance, a salt, and a condensing agent to the surface of a substrate, a step B of immobilizing the selective binding substance to the surface of the substrate, a step C of drying the applied solution to allow the salt in the solution to precipitate on the surface of the substrate, and a step D of using an image detection device to detect a precipitate of the salt formed in the step C, wherein, in the step A, the condensing agent in the solution has a concentration of not less than 30 mM and not more than 80 mM.

A reagent kit comprising a first polypeptide including a part in any one of amino acid sequences (A) to (C), and a second polypeptide including a part in any one of amino acid sequences (A) to (C), which are consistent of different sequences from a sequence of the first polypeptide; (A) an amino acid sequence in SEQ ID NO: 1 with deletion of an amino acid sequence from position 1 to 69 and an amino acid sequence from position 204 to 221, (B) an amino acid sequence in SEQ ID NO: 1 with deletion of an amino acid sequence from position 1 to 69 and deletion or substitution of at least one of amino acid residues at positions 146 to 156, (C) the amino acid sequence (A) or (B) with further deletion of at least one of amino acid residues at positions 70 to 74.

A reagent kit comprising a first polypeptide including a part in any one of amino acid sequences (A) to (C), and a second polypeptide including a part in any one of amino acid sequences (A) to (C), which are consistent of different sequences from a sequence of the first polypeptide; (A) an amino acid sequence in SEQ ID NO: 1 with deletion of an amino acid sequence from position 1 to 69 and an amino acid sequence from position 204 to 221, (B) an amino acid sequence in SEQ ID NO: 1 with deletion of an amino acid sequence from position 1 to 69 and deletion or substitution of at least one of amino acid residues at positions 146 to 156, (C) the amino acid sequence (A) or (B) with further deletion of at least one of amino acid residues at positions 70 to 74.